KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Payables (2019 - 2025)

GoodRx Holdings' Payables history spans 7 years, with the latest figure at $19.4 million for Q4 2025.

  • For Q4 2025, Payables rose 37.26% year-over-year to $19.4 million; the TTM value through Dec 2025 reached $19.4 million, up 37.26%, while the annual FY2025 figure was $19.4 million, 37.26% up from the prior year.
  • Payables for Q4 2025 was $19.4 million at GoodRx Holdings, down from $28.7 million in the prior quarter.
  • Across five years, Payables topped out at $36.3 million in Q4 2023 and bottomed at $6.8 million in Q2 2023.
  • The 5-year median for Payables is $17.1 million (2021), against an average of $19.0 million.
  • The largest annual shift saw Payables soared 203.13% in 2023 before it crashed 62.34% in 2024.
  • A 5-year view of Payables shows it stood at $17.5 million in 2021, then grew by 1.14% to $17.7 million in 2022, then surged by 104.89% to $36.3 million in 2023, then crashed by 61.02% to $14.1 million in 2024, then soared by 37.26% to $19.4 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Payables are $19.4 million (Q4 2025), $28.7 million (Q3 2025), and $25.4 million (Q2 2025).